Trial · NCT02258542
Adverse events712
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 712
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Influenza like illness | General disorders | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | 27 | 783 | 41 |
| other | Influenza like illness | General disorders | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | 30 | 793 | 35 |
| other | Influenza like illness | General disorders | ZONDA - Benralizumab 30 mg q.4 Weeks | 3 | 49 | 3 |
| other | Influenza like illness | General disorders | ZONDA - Benralizumab 30 mg q.8 Weeks | 1 | 49 | 1 |
| other | Bronchitis | Infections and infestations | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | 50 | 783 | 66 |
| other | Bronchitis | Infections and infestations | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | 51 | 793 | 76 |
| other | Bronchitis | Infections and infestations | ZONDA - Benralizumab 30 mg q.4 Weeks | 3 | 49 | 7 |
| other | Bronchitis | Infections and infestations | ZONDA - Benralizumab 30 mg q.8 Weeks | 10 | 49 | 16 |
| other | Upper respiratory tract infection | Infections and infestations | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | 61 | 783 | 95 |
| other | Upper respiratory tract infection | Infections and infestations | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | 56 | 793 | 82 |
| other | Upper respiratory tract infection | Infections and infestations | ZONDA - Benralizumab 30 mg q.4 Weeks | 0 | 49 | 0 |
| other | Upper respiratory tract infection | Infections and infestations | ZONDA - Benralizumab 30 mg q.8 Weeks | 7 | 49 | 8 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | 26 | 783 | 32 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | 20 | 793 | 20 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | ZONDA - Benralizumab 30 mg q.4 Weeks | 5 | 49 | 5 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | ZONDA - Benralizumab 30 mg q.8 Weeks | 0 | 49 | 0 |
| other | Conjunctivitis allergic | Eye disorders | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | 4 | 783 | 5 |
| other | Conjunctivitis allergic | Eye disorders | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | 8 | 793 | 8 |
| other | Conjunctivitis allergic | Eye disorders | ZONDA - Benralizumab 30 mg q.4 Weeks | 3 | 49 | 3 |
| other | Conjunctivitis allergic | Eye disorders | ZONDA - Benralizumab 30 mg q.8 Weeks | 0 | 49 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02258542/events